Why Testing Diabetes and ADHD Drugs for Alzheimer's Makes Surprising Sense

Why Testing Diabetes and ADHD Drugs for Alzheimer's Makes Surprising Sense

Two familiar pills sitting in medicine cabinets around the world—one for blood sugar, one for attention—are now stepping into the spotlight for Alzheimer's disease. Honestly, that sounds weird at first glance. Why would a diabetes medication and an ADHD drug end up in a major dementia study?

Here's the direct answer: researchers in the United Kingdom have launched the AD-SMART trial (Alzheimer's disease Systematic Multi-arm Adaptive Randomised Trial) to test whether metformin and atomoxetine can ease symptoms, protect daily function, and help people living with Alzheimer's. Led by the UK Dementia Research Institute and Alzheimer's Research UK alongside major partners including University College London, Imperial College London, and the University of Oxford, the study plans to recruit around 1,200 participants across more than 30 UK sites, with initial results for the first drugs expected around 2030.

If you've watched dementia research crawl forward for decades, you know the frustration. Building a brand-new drug from scratch takes forever and fails more often than it succeeds. Repurposing medicines that already have years of real-world safety data behind them won't magically cure Alzheimer's overnight, and neither drug is proven to work for it yet. Still, this trial tackles two massive bottlenecks at once: what we test and how fast we test it.

Why Diabetes and ADHD Drugs Enter the Picture

When people hear about repurposing drugs for brain health, they often assume scientists are just throwing darts at a board. They aren't. Both metformin and atomoxetine connect to biological pathways that go haywire in Alzheimer's.

Metformin is a widely prescribed blood glucose-lowering medicine for type 2 diabetes. In AD-SMART, researchers are testing immediate-release oral metformin (up to 2,000 mg per day). Metabolic health and brain health are tightly tangled, and neuroinflammation—chronic, low-grade inflammatory signaling in the brain—can speed up neurodegeneration. Metformin has properties linked to calming inflammatory processes and supporting cellular energy balance, which is why dementia researchers have been eyeing it for years.

Atomoxetine works quite differently. It's a selective noradrenaline reuptake inhibitor used to treat attention-deficit/hyperactivity disorder (ADHD), tested in the trial at oral doses up to 100 mg per day. Noradrenaline plays a huge role in attention, arousal, and brain network communication, and the noradrenergic system takes a hit early in Alzheimer's. Researchers have seen prior signals suggesting atomoxetine can influence processes tied to ongoing degeneration and neuroinflammation.

That said, let's keep expectations grounded. Drug repurposing has plenty of cautionary tales in neurology. A medication can hit a biological target in theory or in early studies and still fall flat in large human trials. Just look at broader metabolic-drug news in dementia: in November 2026, reports highlighted that semaglutide failed to slow the progression of early Alzheimer's in Novo Nordisk's EVOKE and EVOKE+ trials, even while showing effects on brain markers. Biology in the aging human brain is stubborn. Testing metformin and atomoxetine rigorously in AD-SMART is how we find out whether real clinical benefit actually shows up over 18 months.

How a Multi-Arm Adaptive Trial Changes the Math

Traditional Alzheimer's trials usually pit one experimental drug against one placebo group over a long stretch. Run enough of those one-by-one, and a decade vanishes before you get clear answers.

AD-SMART uses a multi-arm, multi-stage platform design. Think of it like a smarter tournament bracket rather than a series of slow, isolated duels. Multiple treatments are tested at the same time against a single shared placebo group.

That design changes the math in three practical ways:

  • Faster timelines: Sharing a placebo group and running arms in parallel means researchers estimate they can more than halve the time typically needed to evaluate Alzheimer's treatments.
  • Smarter resource use: Data gets checked at planned interim stages. If a drug shows no meaningful benefit, the trial can drop that arm early and bring in a new candidate during the initial four-year window.
  • Better odds for participants: Because multiple active options are running alongside a shared control arm, a higher share of participants can receive an active study treatment compared with many classic single-drug designs.

Similar platform approaches have already proved their value in areas like cancer and motor neuron disease. Bringing that structure into symptomatic Alzheimer's disease is a big deal for trial efficiency, even if the scientific hurdle remains steep.

What the Study Actually Measures Over 18 Months

Headlines love quick wins, but Alzheimer's trials live and die by carefully chosen endpoints. In AD-SMART (registered on ClinicalTrials.gov as NCT07724132 and ISRCTN as ISRCTN17108793), participants are followed over an 18-month treatment window alongside standard care.

Rather than looking only at a single lab score, the study tracks outcomes that matter in everyday life:

  1. Daily living function: Changes in practical everyday tasks—such as cooking, showering, and managing routines—measured across baseline and months 6, 12, and 18.
  2. Cognitive symptoms: Memory, problem-solving, and thinking skills assessed in person at regular intervals.
  3. Neuropsychiatric symptoms: Mood, anxiety, and apathy, which often weigh just as heavily on patients and families as memory slips.
  4. Brain imaging and biomarkers: MRI scans at the start and end of the trial, plus blood biomarkers, to help researchers understand structural brain changes and how participants respond.

Eligibility isn't wide open to everyone, either. According to trial registry details, participants generally need to be aged 55 or older with a confirmed clinical diagnosis of Alzheimer's disease or mixed dementia involving Alzheimer's and vascular dementia, an MMSE score of at least 17, confirmatory biomarker evidence (such as pTau-217 blood testing, amyloid PET, or CSF), ability to undergo MRI scans, normal liver function, and a study partner with regular contact. Certain conditions—like other dementias such as Lewy body or frontotemporal dementia, Parkinson's disease, or recent anti-amyloid antibody therapy within 26 weeks prior to randomisation—exclude people from joining.

Common Misconceptions You Should Watch Out For

Whenever repurposed drugs hit the news, misinformation spreads fast. Let's clear up a few traps right away.

Misconception one: "Metformin or atomoxetine is already proven to treat Alzheimer's." Nope. Neither drug is approved for Alzheimer's right now, and their benefit for people living with the disease remains unproven until trial results come in.

Misconception two: "If a drug is safe for diabetes or ADHD, anyone with memory trouble can just take it." Bad idea. Side effects and interactions depend on age, kidney or liver health, heart status, and other medications. For instance, metformin has specific safety guardrails (such as kidney and liver considerations in clinical protocols), and atomoxetine affects blood pressure, heart rate, and mood pathways. Taking either off-label without medical supervision won't shortcut Alzheimer's care and can create real risks.

Misconception three: "Trial results will be out next year." Patience is required here. Evaluation of the first drugs in AD-SMART runs on a multi-year timeline toward 2030, though interim stage reviews can guide decisions along the way.

Practical Next Steps for Patients and Families

If you or someone you love is navigating Alzheimer's or mild cognitive impairment due to Alzheimer's, here's how to turn this news into smart action rather than hype:

  • Don't self-experiment with prescriptions: Keep taking current prescribed treatments as directed, and don't ask for or take metformin or atomoxetine expecting an Alzheimer's fix based on early trial news.
  • Ask your clinician about biomarker and trial readiness: If you're in the UK—or looking at comparable platform trials elsewhere—ask a neurologist or memory clinic whether biomarker testing, imaging eligibility, or research registries make sense for your stage of care.
  • Check official registry details before applying: Review study criteria directly on ClinicalTrials.gov (NCT07724132) or via Alzheimer's Research UK and the UK Dementia Research Institute so you know what visits, MRI scans, and study-partner commitments are involved.
  • Focus on proven day-to-day levers today: While waiting on long-term trial data, managing blood pressure, cardiovascular risk factors, sleep, hearing, physical activity, and tailored symptom support remains the most reliable way to protect day-to-day function right now.
EP

Elena Parker

Elena Parker is a prolific writer and researcher with expertise in digital media, emerging technologies, and social trends shaping the modern world.